摘要
目的观察参七益气活血胶囊治疗慢性心力衰竭气虚血瘀型患者的临床效果。方法选取梅州市中医医院2020年12月至2021年12月收治的气虚血瘀型慢性心力衰竭患者215例,按随机数表法将患者分为对照组107例和治疗组108例,对照组采取西医常规治疗,治疗组在对照组基础上加用参七益气活血胶囊,两组疗程均为4周。治疗结束1个月后,观察患者症状及活动耐量改善情况。治疗结束3个月后复查,比较患者治疗前后NT-proBNP水平、活动耐量、证候积分、心功能参数,判定疗效;并观察主要不良心脏事件(MACE)及治疗安全性。结果治疗后1、3个月两组6 min步行距离、气虚血瘀证候积分均改善,且治疗组改善均优于同期对照组;治疗后两组NT-proBNP水平、超声心动图测量参数均有所改善,且治疗组改善优于对照组;治疗组心功能分级疗效总有效率为91.67%,对照组为78.50%;治疗组心功能分级疗效均优于对照组;治疗组MACE发生率为4.63%低于对照组的13.08%,差异有统计学意义(P<0.05)。结论参七益气活血胶囊治疗慢性心力衰竭气虚血瘀型患者疗效显著,且安全性较高。
Objective To observe the clinical efficacy of Shenqi Yiqi Huoxue Capsules in treating patients with chronic heart failure of Qi deficiency and blood stasis.Methods A total of 215 patients with chronic heart failure of Qi deficiency and blood stasis admitted to Meizhou Hospital of TCM from December 2020 to December 2021 were selected.The patients were divided into a control group 107 cases and a treatment group 108 cases using a random number table method.The control group received routine Western medicine treatment,and the treatment group received Shenqi Yiqi Huoxue Capsules under the treatment of the control group.The treatment courses for both groups were 4 weeks.After one month of treatment,the improvement of patient’s symptoms and exercise tolerance.After three months of treatment,a follow-up examination was conducted to assess the NT-proBNP levels,exercise tolerance,syndrome scores,and cardiac function parameters of patients before and after treatment,in order to determine the therapeutic effect;And the major adverse cardiac events(MACE)and treatment safety were investigated.Results After 1 month and 3 months of treatment,the 6-minute walking distance and the score of Qi deficiency and blood stasis syndrome improved in both groups,and the improvement in the treatment group was better than that in the control group during the same period;After treatment,the levels of NT-proBNP and echocardiographic parameters in both groups improved,and the improvement in the treatment group was better than that in the control group;The total effective rate of cardiac functional grading in the treatment group was 91.67%,while in the control group,it was 78.50%;The treatment group had better therapeutic effects on Qi deficiency and blood stasis syndrome and cardiac functional grading than the control group;The incidence of MACE in both groups was 4.63%in the treatment group,lower than 13.08%in the control group.The above differences were statistically significant(P<0.05).Conclusion Shenqi Yiqi Huoxue Capsules have a significant therapeutic effect and high safety in treating patients with chronic heart failure of Qi deficiency and blood stasis.
作者
张博
钟粤巧
谢钦荣
何耀文
黄墩泉
ZHANG Bo;ZHONG Yueqiao;XIE Qinrong;HE Yaowen;HUANG Dunquan(Department of Cardiovascular Medicine,Meizhou Hospital of TCM,Guangdong,Meizhou 514000,China)
出处
《中国医药科学》
2023年第14期68-71,105,共5页
China Medicine And Pharmacy
基金
广东省梅州市社会发展科技计划项目(2020B059)。
关键词
参七益气活血胶囊
慢性心力衰竭
气虚血瘀证
心功能
Shenqi Yiqi Huoxue Capsules
Chronic heart failure
Qi deficiency and blood stasis syndrome